Ernexa Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 1.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.22M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutic...